The association between serum Perilipin-2 and kidney disease progression of patients with autosomal dominant polycystic kidney disease-Reference-Cited by-同舟云学术

The association between serum Perilipin-2 and kidney disease progression of patients with autosomal dominant polycystic kidney disease

Published:2024-01-29 Issue:1 Volume:4 Page:7-16
ISSN:2791-9250
Container-title:DAHUDER Medical Journal
language:
Short-container-title:

Author:

ÇETİN Mustafa¹^ORCID,EROĞLU Eray²^ORCID,KARAKÜKÇÜ Çiğdem³^ORCID,ZARARSIZ Gökmen⁴^ORCID,ÇIRAK GÜRSOY Ayşenur⁵^ORCID,KOÇYİĞİT İsmail⁶^ORCID

Affiliation:

1. Department of Internal Medicine, Division of Geriatrics , University of Health Sciences , Gulhane Training and Research Hospital

2. Department of Nephrology, Kilis State Hospital,

3. Department of Biochemistry, Erciyes University School of Medicine

4. Department of Biostatistics, Erciyes University School of Medicine

5. Department of Internal Medicine, Dr. Ali Kemal Belviranlı Gynecology and Pediatrics Hospital

6. Department of Nephrology, Erciyes University School of Medicine

Abstract

Objective: We aimed to evaluate the relationship between serum perilipin-2 / adipophilin (PLIN-2 / ADRP) levels and clinical course in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Methods: 80 ADPKD patients with Chronic Kidney Disease (CKD) G1-G4 status, among the patients who were regularly followed up in the nephrology outpatient clinic between 2012 and 2019, were included in the study. CKD-G5 patients were excluded from the study. Baseline PLIN-2/ADRP levels were measured. Patients were divided into 2 groups according to the median serum PLIN-2/ADRP level. During the follow-up period, data such as blood pressure, height-adjusted total kidney volume (HtTKV), proteinuria, complete blood count, and biochemical tests were recorded. Results: In the patients with serum PLIN-2 / ADRP level above the median value (11.675 ng / mL), BMI was significantly higher than the other group (p

Publisher

Dahiliye uzmanlari dernegi (DAHUDER)

Reference23 articles.

1. Cordido A, Besada-Cerecedo L, García-González MA. The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease-A Primer for Clinicians. Front Pediatr. 2017;5:279. Published 2017 Dec 18. doi:10.3389/fped.2017.00279

2. Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013;9(1):2-11. doi:10.2174/1573402111309010002

3. Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2015;30(2):197-203. doi:10.1093/ndt/gfu044

4. Meijer E, Gansevoort RT, de Jong PE, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011;26(8):2445-2453. doi:10.1093/ndt/gfr069

5. Santoro D, Pellicanò V, Visconti L, Trifirò G, Buemi M, Cernaro V. An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease. Expert Opin Investig Drugs. 2015;24(9):1199-1218. doi:10.1517/13543784.2015.1059421